Protagonist Therap (PTGX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec6

Takeda and Protagonist Announce 52-Week Data for Rusfertide and Plan to Seek Regulatory Approval

14:30

Nov27

Protagonist Therapeutics Sees Significant Revenue Growth with Janssen Collaboration

22:45

Nov14

H.C. Wainwright Analyst Reiterates Buy Rating on Protagonist Therapeutics

23:42

Nov9

Protagonist Therapeutics Reports Lower-than-Expected Quarterly Earnings, Stock Price Drops

03:53

Nov7

H.C. Wainwright Maintains Buy Rating on Protagonist Therapeutics

12:02

Protagonist Therap released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 4.712 M (forecast USD 4.136 M), actual EPS USD -0.62 (forecast USD -0.6375)

04:00

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 4.712 M, Net Income -39.34 M, EPS -0.62

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 5.546 M, Net Income -34.77 M, EPS -0.5499

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 28.32 M, Net Income -11.66 M, EPS -0.1899

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change